Healthcare resource use and associated costs among patients with Crohn’s disease and ulcerative colitis who initiated ustekinumab treatment through BIOADVANCE® program

Project ID: P2022-123/ 2024 0970 346 000

Research Question/Objectives

Primary objective:
1. To compare yearly HCRU and associated costs between 1 year prior to index date and yearly HCRU and associated costs up to 4 years following the index date among patients in Ontario with CD and UC that have initiated ustekinumab treatment through Janssen BIOADVANCE®.

Secondary objectives:
1. To describe patient demographic and clinical characteristics at index date or in 1 year before the index date among the study population described in the primary objective
2. To compare yearly HCRU and associated costs between 1 year prior to index date and yearly HCRU and associated costs up to 4 years following the index date among patients in Ontario with CD and UC that have initiated and continued ustekinumab treatment through Janssen BIOADVANCE®
3. To assess the association of persistence on ustekinumab at 12 months following the index date with the subsequent yearly HCRU and associated costs, if sample size is sufficient
4. To assess the association of previous biologic experience at the index date with the yearly HCRU and associated costs following the index date, if sample size is sufficient
5. To evaluate the yearly HCRU and associated costs incurred after the index date and during the treatment period prior to the pre-COVID-19 pandemic period, if sample size is sufficient

Exploratory objectives – if feasible:
1. To evaluate yearly HCRU and associated costs after ustekinumab treatment discontinuation in the sub-cohort of patients who discontinued ustekinumab during the study period.

Results: In progress